Estrella Immunopharma Files 10-K/A Amendment
Ticker: ESLAW · Form: 10-K/A · Filed: Oct 28, 2024 · CIK: 1844417
Sentiment: neutral
Topics: amendment, annual-report, biotech
TL;DR
Estrella Immunopharma filed an amended 10-K for FY24, check for updates.
AI Summary
Estrella Immunopharma, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended June 30, 2024. The company, formerly known as TradeUP Acquisition Corp. until February 4, 2021, is based in Emeryville, CA, and operates in the biological products sector. This filing is an amendment to their previous report.
Why It Matters
This filing provides updated or corrected information for Estrella Immunopharma's annual financial performance and business operations, crucial for investors to assess the company's current standing.
Risk Assessment
Risk Level: low — This is a routine amendment to an annual report, not indicating new or significant risks.
Key Numbers
- 001-40608 — SEC File Number (Identifies the company's filings with the SEC.)
- 86-1314502 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Estrella Immunopharma, Inc. (company) — Registrant
- June 30, 2024 (date) — Fiscal Year End
- TradeUP Acquisition Corp. (company) — Former Company Name
- February 4, 2021 (date) — Date of Name Change
- Emeryville, CA (location) — Company Headquarters
FAQ
What specific changes or additions are made in this Amendment No. 1 to the 10-K filing?
The filing is an amendment to the Form 10-K for the fiscal year ended June 30, 2024, indicating that the original filing required correction or supplementation.
When was Estrella Immunopharma, Inc. previously known by another name?
The company was formerly known as TradeUP Acquisition Corp. until February 4, 2021.
What is the primary business of Estrella Immunopharma, Inc. according to the filing?
The company is classified under STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
Where is Estrella Immunopharma, Inc. located?
The company's business and mailing address is 5858 Horton Street, Suite 370, Emeryville, CA 94608.
What is the SEC file number for Estrella Immunopharma, Inc.?
The SEC file number is 001-40608.
Filing Stats: 4,553 words · 18 min read · ~15 pages · Grade level 12.3 · Accepted 2024-10-28 17:03:29
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ESLA The Nasdaq Stock Market
- $11.50 — mon Stock, each at an exercise price of $11.50 per share ESLAW The Nasdaq Stock Market
- $1.01 — gistrant, based on the closing price of $1.01 per share of the Registrant's ordinary
- $20,000 — member of the scientific advisory board $20,000 per year for his or her services under
Filing Documents
- ea0218384-10ka1_estrella.htm (10-K/A) — 295KB
- ea021838401ex31-3_estrella.htm (EX-31.3) — 3KB
- ea021838401ex31-4_estrella.htm (EX-31.4) — 3KB
- 0001213900-24-091250.txt ( ) — 589KB
- esla-20240630.xsd (EX-101.SCH) — 4KB
- esla-20240630_def.xml (EX-101.DEF) — 19KB
- esla-20240630_lab.xml (EX-101.LAB) — 39KB
- esla-20240630_pre.xml (EX-101.PRE) — 20KB
- ea0218384-10ka1_estrella_htm.xml (XML) — 9KB
Executive Compensation
Executive Compensation 11 Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 16 Item 13. Certain Relationships and Related Transactions, and Director Independence 18 Item 14. Principal Accountant Fees and Services 20 PART IV 21 Item 15. Exhibits and Financial Statement Schedules 21 i PART III
Directors, Executive Officers and Corporate Governance
Item 10. Directors, Executive Officers and Corporate Governance. Management and Board of Directors Our Board of Directors ("Board") is comprised of six directors. In addition to the information set forth below regarding our directors and the skills that led our Board to conclude that these individuals should serve as directors, we also believe that all of our directors have a reputation for integrity, honesty and adherence to the highest ethical standards. We believe they each have demonstrated business acumen and an ability to exercise sound judgment, as well as a commitment of service to our Company and to their Board duties. The following persons currently serve as Estrella's executive officers and directors. For biographical information concerning the executive officers and directors, see below. Name Age Position(s) Held Executive Officers Dr. Cheng Liu 56 Chief Executive Officer, President and Director Peter Xu 52 Chief Financial Officer Non-Employee Directors Hong Zhang 54 Director and Chairperson of the Board Dr. Marsha Roberts 53 Director Fan Wu 49 Director Janelle Wu 49 Director Pei Xu 40 Director Executive Officers Cheng Liu, PhD, Chief Executive Officer and President Dr. Liu serves as Estrella's CEO and President. He is the Founder, President, and CEO of Eureka. Prior to founding Eureka, Dr. Liu was a Principal Scientist in antibody drug discovery at Chiron (now Novartis). With over 20 years of experience in the field, he holds more than 500 patents and published patent applications of which over 100 patents have issued worldwide and has authored numerous peer-reviewed papers on cancer immunotherapy. He is the inventor of multiple first-in-class, clinical-stage cancer drugs against various tumor targets, including drugs targeting CSF1 for the treatment of bone metastasis, BCMA for multiple myeloma, and AFP and GPC3 for liver cancer. In 2007, he was awarded Special U.S. Congressional Recognitio